Newport Beach, California, May 10, 2024–(BUSINESS WIRE)–Evolus, Inc. (NASDAQ: EOLS), a performance beauty company focused on building an aesthetic portfolio of consumer brands, today announced the appointment of Chief Financial Officer Sandrać»It was announced that Mr. Beaver was awarded an award. Excellent CFO of a listed company By Orange County Business Journal. This award is given to a CFO who has demonstrated outstanding performance as a corporate steward.
Since joining Evolus in 2022, Mrs. Beaver has played a key role in the company's continued growth and success. In 2023, she supported and led the financial execution of the company's licensing agreements and other milestones. This expanded the product portfolio with the addition of late-stage dermal fillers in the US and European markets, expanding the total estimated addressable market by 78% to approximately $6. a billion. She also played a key role in supporting the geographic expansion of the company's commercial footprint into Austria, Germany and Italy. Sandra will continue to lead her organization to financial success, guiding critical processes and driving smart strategic decisions to grow the company's portfolio while maintaining operating expense discipline.
“On behalf of the entire Evolus team, we congratulate Sandra on receiving this well-deserved recognition. In her role as CFO, Sandra's strong strategic leadership and vision have contributed to our success. With her critical insights, outstanding performance, and many accomplishments, Sandra's contributions to our company have enabled us to move through complex business scenarios seamlessly and with precision, resulting in licensing agreements to expand our product portfolio. “They have not only paved the way for us to secure our financial portfolio, but have also played a pivotal role in continuing the rapid growth of our business,” said David, President and CEO of Evolus. Moatazedi says.
About Evolus Co., Ltd.
Evolus (NASDAQ: EOLS) is a global performance beauty company that is evolving the aesthetic neurotoxin market for the next generation of beauty consumers through a unique customer-centric business model and innovative digital platform. Our mission is to become a global multi-product aesthetic company based on our flagship product Jeuveau.Ā® (PrabotulinumtoxinA-xvfs) is the first and only neurotoxin exclusively for aesthetics, manufactured in a state-of-the-art facility using Hi-Pureā¢ technology. Evolus expands its product portfolio with definitive agreements to become exclusive U.S. distributor for Evolysseā¢ and exclusive European distributor for Estyme.Ā®, a unique dermal filler product line currently in late stage development. Visit www.evolus.com and follow us on LinkedIn. XInstagram or Facebook.
JeuveauĀ® and NuceibaĀ®Evolysse is a registered trademark.ā¢ is a trademark of Evolus.
high pureā¢ is a trademark of Daio Pharmaceutical Co., Ltd.
EstemĀ® is a trademark of Symatese Aesthetics SAS
View source version on businesswire.com. https://www.businesswire.com/news/home/20240510629398/en/
contact address
Evolus contact information:
Investor:
Nareg Sagerian
Vice President, Head of Global Investor Relations and Corporate Communications
Phone: 248-202-9267
Email: ir@evolus.com
media:
Email: media@evolus.com